公开(公告)号：US20240043459A1

公开(公告)日：2024-02-08

申请号：US18486487

申请日：2023-10-13

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey Barker

IPC分类号： C07F9/6574

CPC分类号： C07F9/65742 ,  C07B2200/13

摘要： Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.

公开(公告)号：US20220016137A1

公开(公告)日：2022-01-20

申请号：US17299998

申请日：2019-12-04

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/662 ,  A61P11/00 ,  A61P29/00 ,  A61P17/02 ,  A61P1/16 ,  A61K31/665

摘要： The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：US12102646B2

公开(公告)日：2024-10-01

申请号：US17299998

申请日：2019-12-04

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/662 ,  A61K31/665 ,  A61P1/16 ,  A61P11/00 ,  A61P17/02 ,  A61P29/00

CPC分类号： A61K31/662 ,  A61K31/665 ,  A61P1/16 ,  A61P11/00 ,  A61P17/02 ,  A61P29/00

摘要： The present disclosure is directed to methods of treating fibrotic conditions and inflammation by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：US20210024554A1

公开(公告)日：2021-01-28

申请号：US16982022

申请日：2019-03-18

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey Barker

IPC分类号： C07F9/6574

摘要： Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.

公开(公告)号：US11787828B2

公开(公告)日：2023-10-17

申请号：US16982022

申请日：2019-03-18

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey Barker

IPC分类号： C07F9/6574

CPC分类号： C07F9/65742 ,  C07B2200/13

摘要： Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.

公开(公告)号：US20220016136A1

公开(公告)日：2022-01-20

申请号：US17311014

申请日：2019-12-04

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune

IPC分类号： A61K31/661 ,  A61K31/366 ,  A61K31/192 ,  A61K31/662 ,  A61K31/664 ,  A61K31/66 ,  A61K31/404 ,  A61K31/40 ,  A61K31/501 ,  A61K31/216 ,  A61K31/575 ,  A61K31/397 ,  A61K31/46 ,  A61K31/422 ,  A61K31/42 ,  A61K31/55 ,  A61K31/4184 ,  A61K31/554 ,  A61K31/495 ,  A61K31/4412 ,  A61K31/415 ,  A61K31/41 ,  A61K31/5377 ,  A61K31/341 ,  A61K31/4192 ,  A61K31/381 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/553 ,  A61K31/4245 ,  A61K31/435 ,  A61K31/506 ,  A61K31/4353 ,  A61K31/551 ,  A61K38/26 ,  A61K38/28 ,  A61K38/18 ,  A61K45/06 ,  A61P1/16

摘要： The present disclosure is directed toward the use of thyroid receptor agonists of pharmaceutically acceptable salts thereof, in combination with a second pharmaceutical agent for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

公开(公告)号：US20200179412A1

公开(公告)日：2020-06-11

申请号：US16617471

申请日：2018-06-04

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/683 ,  A61K31/665 ,  A61K31/662 ,  A61P19/04

摘要： The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：US20240189332A1

公开(公告)日：2024-06-13

申请号：US18224387

申请日：2023-07-20

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/683 ,  A61K31/662 ,  A61K31/665 ,  A61P19/04

CPC分类号： A61K31/683 ,  A61K31/662 ,  A61K31/665 ,  A61P19/04

摘要： The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β—dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：US11707472B2

公开(公告)日：2023-07-25

申请号：US16617471

申请日：2018-06-04

申请人： Viking Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Geoffrey E. Barker

IPC分类号： A61K31/662 ,  A61K31/665 ,  A61K31/683 ,  A61P19/04

CPC分类号： A61K31/683 ,  A61K31/662 ,  A61K31/665 ,  A61P19/04

摘要： The present disclosure is directed to methods of treating fibrotic conditions by administration of TRβ agonists. The disclosure provides methods wherein the abnormal deposition of extracellular matrix components, such as collagen, keratin, or elastin, is reduced, either through interaction of TRβ agonists with TGF-β-dependent inflammatory pathways, or by other mechanisms, thereby ameliorating fibrotic symptoms.

公开(公告)号：US20190255080A1

公开(公告)日：2019-08-22

申请号：US16333513

申请日：2017-09-13

申请人： Viking Therapeutics, Inc. ,  Metabasis Therapeutics, Inc.

发明人： Brian Lian ,  Hiroko Masamune ,  Mark Erion ,  Bruce Ito

IPC分类号： A61K31/662 ,  A61K31/665 ,  A61P3/06 ,  A61P3/04 ,  A61P3/10 ,  A61P1/16 ,  A61P9/10 ,  A61P5/14

摘要： The present disclosure is directed to methods of administration of thyroid hormone receptor agonists. The disclosure provides methods wherein the activity of the given thyroid receptor agonists in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related disorders is maintained, while thyroid-related and thyroid axis-related side effects are reduced or eliminated.